- Home
- VYGR
as of 02-24-2026 3:46pm EST
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 194.0M | IPO Year: | 2015 |
| Target Price: | $17.00 | AVG Volume (30 days): | 527.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -1.57 | EPS Growth: | -138.05 |
| 52 Week Low/High: | $2.65 - $5.55 | Next Earning Date: | 01-01-0001 |
| Revenue: | $10,135,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -54.7% | Revenue Growth (next year): | 71.77% |
| P/E Ratio: | -2.27 | Index: | N/A |
| Free Cash Flow: | -18831000.0 | FCF Growth: | N/A |
AI-Powered VYGR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Voyager Therapeutics Inc. (VYGR)
President and CEO
Avg Cost/Share
$3.41
Shares
11,732
Total Value
$40,006.12
Owned After
498,257
SEC Form 4
COO & CBO
Avg Cost/Share
$3.44
Shares
3,882
Total Value
$13,354.08
Owned After
206,196
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$3.44
Shares
3,301
Total Value
$11,355.44
Owned After
149,892
SEC Form 4
President and CEO
Avg Cost/Share
$3.78
Shares
12,192
Total Value
$46,085.76
Owned After
498,257
SEC Form 4
COO & CBO
Avg Cost/Share
$3.85
Shares
4,569
Total Value
$17,590.65
Owned After
206,196
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$3.85
Shares
3,525
Total Value
$13,571.25
Owned After
149,892
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sandrock Alfred | VYGR | President and CEO | Feb 18, 2026 | Sell | $3.41 | 11,732 | $40,006.12 | 498,257 | |
| Swartz Robin | VYGR | COO & CBO | Feb 18, 2026 | Sell | $3.44 | 3,882 | $13,354.08 | 206,196 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Feb 18, 2026 | Sell | $3.44 | 3,301 | $11,355.44 | 149,892 | |
| Sandrock Alfred | VYGR | President and CEO | Feb 10, 2026 | Sell | $3.78 | 12,192 | $46,085.76 | 498,257 | |
| Swartz Robin | VYGR | COO & CBO | Feb 10, 2026 | Sell | $3.85 | 4,569 | $17,590.65 | 206,196 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Feb 10, 2026 | Sell | $3.85 | 3,525 | $13,571.25 | 149,892 |
Compare VYGR vs Leading Stocks
See how VYGR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VYGR Voyager Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.